Numerous studies in the field of clinical trials have demonstrated the effectiveness of different generations of tyrosine kinase inhibitors (TKIs), such as afatinib [50], alectinib, abemaciclib [51], crizotinib [52], erlotinib [53], gefitinib, lorlatinib, lazertinib [54], and osimertinib [55], in treating advanced NSCLC patients with specific EGFR, ALK, and KRAS mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.